SAS Output

21-OCT-2018 6:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 440 212
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 266 132
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 464 209
  S1706 Breast, Inflammatory, RT +/- Olaparib 12-SEP-18 0 7
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 268 121
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 473 244
  A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 230
  A221405 Breast, ET interruption, Pregnancy Outcomes 15-OCT-15 0 68
  B51 Breast, Regional Nodal XRT 22-AUG-13 400 212
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 439 186
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 98 34
  E2112 Brst,Adv,Exemestane+/-Entinostat 02-JAN-14 294 162
  EA1151 Brst, Tomosynthesis Mammographic Screening 06-JUL-17 0 74
  NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA 24-DEC-14 0 136
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 442 223
  NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 13-APR-17 0 11
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 13 17
  S1417CD Colorectal, Cost Cohort Study 13-MAY-16 123 30
  S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 0 46
  A011104 Preoperative Breast MRI 21-FEB-14 137 46
  A191402C PROS, Testing Decision Aids for Minority Men 14-JUL-17 0 10
  EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer 17-MAY-18 0 12
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 306 159
  A071102 GBM, adj TMZ +/- Veliparib 19-SEP-14 354 146
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 295 110
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 262 118
  EAY131 MATCH 12-AUG-15 369 207
 
GI S1613 mCRC, Adv/Met, TP vs CETIRI 09-OCT-17 0 128
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 57
  A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC 12-SEP-17 0 39
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 188 75
  EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 01-FEB-17 0 1
  N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX 13-JAN-12 0 157
  NRGGI002 Rectal, Ph II, Sensitization using TNT 12-OCT-16 352 149
  NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy 07-NOV-17 0 35
 
GU S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 209 88
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 151 63
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 203 93
  S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum 17-SEP-18 0 22
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 55 34
  A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 21-SEP-17 0 110
  EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) 02-FEB-17 0 140
  EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) 08-FEB-18 0 8
  NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel 30-DEC-16 0 118
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 164
 
LEUK S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP 01-APR-14 3 3
  S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics 22-DEC-17 0 92
  S1712 CML, chronic phase, TKI +/- Ruxolitinib 20-JUL-18 0 47
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 168 83
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 142 71
  NHLBIMDS LEUK, National MDS Study 05-APR-16 266 113
 
LUNG S1400 SCCA,Adv, Biomarker Master 15-JUN-14 435 204
  S1400F Non-Match: MEDI4736 + Tremelimumab 02-OCT-17 0 210
  S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 03-NOV-17 0 26
  S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 09-AUG-18 0 19
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 248
  A151216 ALCHEMIST0 - screening 06-FEB-14 478 249
  C30610 SCLC, Thoracic RT 21-MAR-08 211 116
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 470 248
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 448 242
  EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo 02-MAY-18 0 114
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 327 150
 
LYMPH S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 10-AUG-17 0 104
  A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 154 69
  EA4151 Lymph, AHCT +/-Ritux, MRD Neg 29-AUG-17 0 58
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 224 99
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 89 42
  S1607 MELAN, Adv, T-VEC, MK-3475 02-OCT-17 0 18
  S1616 MELAN, Adv, Ipilimumab Nivolumab 17-JUL-17 0 94
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 348 141
  EA6141 Melan, Avd, Nivolumab+Ipi Sargmostim 01-MAR-16 314 134
 
MMYEL S1702 AL Amyloidosis, Relapsed, Isatuximab 08-MAR-18 0 56
  E1A11 MM, frontline, BLD vs CLD 22-NOV-13 360 160
 
OTHER A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II 26-JAN-15 234 82
  A091305 HN, Adv, Thyroid PPAR agonist + Chemo 01-SEP-14 85 27
  A091401 Sarc, 18-JUN-15 238 99
  A091404 HN, AR+, Enzalutamide 25-SEP-15 76 40
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 0 67
  EAF151 Brain, GBM, Bev, Blood Volume 14-APR-17 0 33
  EAQ152 Communication & education in tumor profiling 26-SEP-16 168 77
  G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT 12-APR-10 0 74
  N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC 22-SEP-09 163 81
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 96
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 324 141
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 200 74
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 204 82
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 235 103
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 205 76
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 13 6
 
SURV S1316 Compar. Effectiv. Trial for MBO 01-AUG-14 7 10
  S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 0 98
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 44
  EA9131 Leuk, Strategy to decrease early APL deaths 16-AUG-17 0 24
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 87 37
  A221505 Brst, Hypofractionated Post Mast Rad 01-FEB-18 0 9
  NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT 28-JUL-17 0 116